Papers/PMID:34663411
Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study.
Critical care (London, England)2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Zn(2+) — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“At multivariable Cox proportional hazards regression analyses, the 30-day mortality was lower in patients who received zinc sulfate (HR 0.52 CI 0.29, 0.92; p = 0.03).”
Quoted verbatim from Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study.. - Study
- cohort
- Dose
- zinc sulfate 220 mg (50 mg elemental zinc) enteral tablet once daily
- Population
- Critically ill adults with COVID-19 in two Saudi ICUs, propensity-score matched 1:1, zinc sulfate newly started in ICU versus no zinc
Effect 0.52 hazard ratio, 95% CI 0.29 to 0.92
Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study.2021PMID:34663411Permalink